The European Commission has approved the use of the CF therapy Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
Aug. 31, 2012
|
1 min read
Aug. 31, 2012
|
1 min read
July 27, 2012
|
1 min read
The European Medicines Agency (EMA) announced today that it has recommended the approval of the CF drug Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
May 25, 2012
|
2 min read
Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments
April 25, 2012
|
3 min read
The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.
March 2, 2012
|
1 min read
Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
Jan. 31, 2012
|
5 min read